Expression Of Has-miR-141in Serum Of Endometrial Cancer And Its Clinical Significance

Objective and Content:So far, curettage pathology remains an important method in preoperative diagnosis of endometrial cancer, but the majority of clinical studies found that the overall accuracy in diagnosis of endometrial carcinoma histological grade and type II endometrial cancer were low, we can not predict whether patients with lymph node metastasis, and also it is an invasive operation. Currently, CA125and CA199commonly used as molecular indicators in clinical diagnosis and treatment of endometrial carcinoma, but its sensitivity in diagnosis of endometrial cancer is not high. Looking for serum biomarkers associated with endometrial cancer, this study was to investigate the has-miR-141(Homo sapiens miR-141, miR-141) in the serum of endometrial carcinoma patients and its clinical significance.Methods:Collected55cases blood specimens before surgery operation from Sep.2012to Dec.2013, and collected12cases preoperative serum of uterine fibroids patients with normal endometrium and5cases blood specimens from the health of volunteers in comparison. Real-time quantity PCR was used to detect the expression of has-miR-141in those specimens and using Graphpad Prism5software analyzed clinical pathological with the expression of has-miR-141in endometrial cancer.Results:The expression of has-miR-141was (2.6295±2.038) in endometrial cancer, which was significant higher than that in control group(P<0.05). The expressions of has-miR-141were (2.182±0.239) and (5.261±0.836) between endometrioid and non-endometrioid adenocarcinoma, and there were significant difference(P<0.05). The expression of has-miR-141were (4.846±0.4114) and (1.363±0.0903) times between lymph node metastasis and without lymph node metastasis in endometrial cancer, in which there were significant difference (P<0.001). The expressions were (2.030±0.2760) and (3.863±0.5308) times in stage Ⅰ-Ⅱ and Ⅲ-Ⅳ endometrial cancer, respectively, in which there were significant difference(P<0.05). The expression were(2.544±0.4728),(2.614±0.4766),(2.775±0.5114) in well, moderately and poorly differentiated endometrial cancer, respectively, while there were not significant difference (P>0.05).Conclusion:Has-miR-141is closely related to the occurance of endometrial cancer, especially to the lymph node metastasis in endometrial cancer. It maybe used as serum biomarkers of lymph node metastasis and as independent prognostic factors, accordingly, it is useful in early diagnosis and treatment of endometrial cancer.